# Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST

> **NCT00331721** · PHASE2 · TERMINATED · sponsor: **PAION Deutschland GmbH** · enrollment: 24 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Enecadin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00331721
- **Lead sponsor:** PAION Deutschland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Scientific data called into question the viability of the substance class
- **Last updated:** 2008-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331721, "Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00331721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*